原発性硬化性胆管炎(Primary Sclerosing Cholangitis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Sclerosing Cholangitis Overview 6
Therapeutics Development 7
Pipeline Products for Primary Sclerosing Cholangitis – Overview 7
Pipeline Products for Primary Sclerosing Cholangitis – Comparative Analysis 8
Primary Sclerosing Cholangitis – Therapeutics under Development by Companies 9
Primary Sclerosing Cholangitis – Pipeline Products Glance 10
Clinical Stage Products 10
Primary Sclerosing Cholangitis – Products under Development by Companies 11
Primary Sclerosing Cholangitis – Companies Involved in Therapeutics Development 12
Biotie Therapies Corp. 12
ChemoCentryx, Inc. 13
Dr. Falk Pharma GmbH 14
Gilead Sciences, Inc. 15
Intercept Pharmaceuticals, Inc. 16
Shire Plc 17
Primary Sclerosing Cholangitis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BTT-1023 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CCX-507 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
norursodeoxycholic acid – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
obeticholic acid – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SHP-625 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
simtuzumab – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Primary Sclerosing Cholangitis – Recent Pipeline Updates 37
Primary Sclerosing Cholangitis – Product Development Milestones 45
Featured News & Press Releases 45
Jul 24, 2014: Clinical study with Biotie’s BTT1023 in primary sclerosing cholangitis awarded external grant funding 45
Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases 45
Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49